181 related articles for article (PubMed ID: 22274570)
1. OnabotulinumtoxinA in pediatric chronic daily headache.
Kabbouche M; O'Brien H; Hershey AD
Curr Neurol Neurosci Rep; 2012 Apr; 12(2):114-7. PubMed ID: 22274570
[TBL] [Abstract][Full Text] [Related]
2. Experience with botulinum toxin type A in medically intractable pediatric chronic daily headache.
Ahmed K; Oas KH; Mack KJ; Garza I
Pediatr Neurol; 2010 Nov; 43(5):316-9. PubMed ID: 20933173
[TBL] [Abstract][Full Text] [Related]
3. OnabotulinumtoxinA (BOTOX®): a review of its use in the prophylaxis of headaches in adults with chronic migraine.
Frampton JE
Drugs; 2012 Apr; 72(6):825-45. PubMed ID: 22468643
[TBL] [Abstract][Full Text] [Related]
4. Effects of onabotulinumtoxinA treatment in chronic migraine patients with and without daily headache at baseline: results from the COMPEL Study.
Young WB; Ivan Lopez J; Rothrock JF; Orejudos A; Manack Adams A; Lipton RB; Blumenfeld AM
J Headache Pain; 2019 Feb; 20(1):12. PubMed ID: 30709333
[TBL] [Abstract][Full Text] [Related]
5. The Use of Botulinum Toxin Type A in Medically Refractory Pediatric Patients With Chronic Daily Headaches and Its Impact on the Quality of Life.
Akbar A; Ford J; Tripathi S
J Child Neurol; 2024 Jan; 39(1-2):55-60. PubMed ID: 38351705
[No Abstract] [Full Text] [Related]
6. OnabotulinumtoxinA for the treatment of headache: an updated review.
Talbet JH; Elnahry AG
J Integr Neurosci; 2022 Jan; 21(1):37. PubMed ID: 35164473
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of onabotulinumtoxinA versus oral migraine prophylactic medications on headache-related resource utilization in the management of chronic migraine: Retrospective analysis of a US-based insurance claims database.
Hepp Z; Rosen NL; Gillard PG; Varon SF; Mathew N; Dodick DW
Cephalalgia; 2016 Aug; 36(9):862-74. PubMed ID: 26692400
[TBL] [Abstract][Full Text] [Related]
8. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.
Aurora SK; Dodick DW; Turkel CC; DeGryse RE; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Cephalalgia; 2010 Jul; 30(7):793-803. PubMed ID: 20647170
[TBL] [Abstract][Full Text] [Related]
9. Clinical profile of botulinum toxin A in patients with chronic headaches and cervical dystonia: a prospective, open-label, longitudinal study conducted in a naturalistic clinical practice setting.
Dowson AJ; Kilminster SG; Salt R
Drugs R D; 2008; 9(3):147-58. PubMed ID: 18457467
[TBL] [Abstract][Full Text] [Related]
10. OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
Silberstein SD; Blumenfeld AM; Cady RK; Turner IM; Lipton RB; Diener HC; Aurora SK; Sirimanne M; DeGryse RE; Turkel CC; Dodick DW
J Neurol Sci; 2013 Aug; 331(1-2):48-56. PubMed ID: 23790235
[TBL] [Abstract][Full Text] [Related]
11. Concurrent onabotulinumtoxinA treatment of cervical dystonia and concomitant migraine.
Winner PK; Sadowsky CH; Martinez WC; Zuniga JA; Poulette A
Headache; 2012 Sep; 52(8):1219-25. PubMed ID: 22607530
[TBL] [Abstract][Full Text] [Related]
12. Real-world effectiveness of onabotulinumtoxinA treatment for the prevention of headaches in adults with chronic migraine in Australia: a retrospective study.
Stark C; Stark R; Limberg N; Rodrigues J; Cordato D; Schwartz R; Jukic R
J Headache Pain; 2019 Jul; 20(1):81. PubMed ID: 31307383
[TBL] [Abstract][Full Text] [Related]
13. Sequential administration of peripheral nerve blocks and onabotulinumtoxinA for the treatment of chronic migraine and other headache disorders-A retrospective tolerability and safety study.
Anderson CC; Iser CR; Hirte IL; Boddu S; Girardo ME; VanderPluym JH; Starling AJ
Headache; 2024 Jun; 64(6):663-673. PubMed ID: 38700250
[TBL] [Abstract][Full Text] [Related]
14. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.
Dodick DW; Turkel CC; DeGryse RE; Aurora SK; Silberstein SD; Lipton RB; Diener HC; Brin MF;
Headache; 2010 Jun; 50(6):921-36. PubMed ID: 20487038
[TBL] [Abstract][Full Text] [Related]
15. OnabotulinumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program.
Aurora SK; Winner P; Freeman MC; Spierings EL; Heiring JO; DeGryse RE; VanDenburgh AM; Nolan ME; Turkel CC
Headache; 2011 Oct; 51(9):1358-73. PubMed ID: 21883197
[TBL] [Abstract][Full Text] [Related]
16. A multi-center double-blind pilot comparison of onabotulinumtoxinA and topiramate for the prophylactic treatment of chronic migraine.
Cady RK; Schreiber CP; Porter JA; Blumenfeld AM; Farmer KU
Headache; 2011 Jan; 51(1):21-32. PubMed ID: 21070228
[TBL] [Abstract][Full Text] [Related]
17. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.
Silberstein SD; Dodick DW; Aurora SK; Diener HC; DeGryse RE; Lipton RB; Turkel CC
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):996-1001. PubMed ID: 25500317
[TBL] [Abstract][Full Text] [Related]
18. Botox treatment for migraine and chronic daily headache in adolescents.
Chan VW; McCabe EJ; MacGregor DL
J Neurosci Nurs; 2009 Oct; 41(5):235-43. PubMed ID: 19835236
[TBL] [Abstract][Full Text] [Related]
19. OnabotulinumtoxinA (BOTOX®): a guide to its use in preventing headaches in adults with chronic migraine.
Lyseng-Williamson KA; Frampton JE
CNS Drugs; 2012 Aug; 26(8):717-23. PubMed ID: 22784019
[TBL] [Abstract][Full Text] [Related]
20. Botulinum toxin type A and acute drug costs in migraine with triptan overuse.
Christie SN; Giammarco R; Gawel M; Mackie G; Gladstone J; Becker WJ
Can J Neurol Sci; 2010 Sep; 37(5):588-94. PubMed ID: 21059503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
